Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 as a Monotherapy in Non-Squamous Non-Small Cell Lung Cancer Patients

NCT02340208 is registered in ClinicalTrials.gov with Helix BioPharma Corporation as lead sponsor.

NCT NCT02340208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02340208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 as a Monotherapy in Non-Squamous Non-Small Cell Lung Cancer Patients
Lead sponsor
Helix BioPharma Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2012
Completion date
December 20, 2017
Enrollment
76 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer